Jagsonpal Pharmaceuticals Share Price

Promoted by Rajpal Singh Kochhar in August, 1978, Jagsonpal Pharmaceuticals Limited is engaged in the manufacture and marketing bulk drugs and pharmaceuticals at its plant at Faridabad in Haryana. The Company has adopted the strategy of clubbing all its products in seven groups for effective marketing and reducing costs. Simultaneously, it has geared up to set up an ultra modern multipurpose basic drugs and formulation plant through its subsidiary, Jagsonpal Exports India Pvt Ltd.The company has a strategic alliance with Fidia Spa, Italy and B Spofola, Czechoslovakia to manufacture sophisticated drugs in India. It has tied up with another Israelbased company, Makhteshim Chemical Works, for acquiring the marketing rights of an antioxidant product. In 1994, the company has also promoted Aresco Financial Services, a new financial company.The Companys RD activities have resulted in manufacturing process upgradation, improving packaging, and cost containment. Its RD activities are geared towards development of new product technologies which can be commercialised in future.It has tied up with Lycored Natural Products Industries (LNP) of Israel, to launch a completely natural Lycopene bioactive product, Lycored, in India and SouthEast Asia.In the fiscal 2001, the companys sales grew by 15% to Rs 136.52 crore and the profit at the net level was up 8% to Rs 10.15 crore. This was achieved against heavy odds, such as, sluggish market trends, lower growth rate of the industry and severe competition from drug majors. However the company has introduced various measures to counter the above factors so as to achieve continued growth and opportunity.The new manufacturing facility at Pantnagar, Uttarakhand started production in April 2009. The Company launched two brands, Divatrone and ProRetro in the market segment, Dydrogesterone, which was earlier dominated by a global pharma Company in August, 2021.On June 27, 2022, Infinity Holdings, an Indiafocused investment group acquired control over the Company consequent to acquisition of 43.73% of equity capital and became Promoters of the Company. The Company identified several products as part of new launches such as Indocap Gel, Lycored Plus, MemUp, Queezy ER to enhance healthcare professionals confidence and improve patient outcomes in 202324. It acquired the India and Bhutan business of Yash Pharma in June, 2024.

As of 22 Jan 2026, Jagsonpal Pharmaceuticals share price is ₹165.3. The stock opened at ₹163 and had closed at ₹164.4 the previous day. During today’s trading session, Jagsonpal Pharmaceuticals share price moved between ₹155.00 and ₹169.67, with an average price for the day of ₹162.33. Over the last 52 weeks, the stock has recorded a low of ₹155.00 and a high of ₹301.65. In terms of performance, Jagsonpal Pharmaceuticals share price has declined by 33.6% over the past six months and has declined by 22.13% over the last year.